RBR-7b5hhk
Completed
Phase 1
In vivo evaluation and monitoring with nanosensors effect hypoglycemic of cucurbita ficifolia Bouché in type 2 diabetic patients
Embrapa Hortaliças0 sitesAugust 23, 2016
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Test of tolerance to abnormal glucose and insulin-dependent diabetes mellitus.
- Sponsor
- Embrapa Hortaliças
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Individuals diagnosed with pre\-diabetes (\> 100 to \< 125 mg/dL) and individuals diagnosed with type 2 diabetes mellitus (\> 126 to \< 300 mg/dL).
Exclusion Criteria
- •Individuals diagnosed with Type 2 diabetes for over 6 months with blood glucose \> 300 mg/dL.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaNCT03656835Ohio State University Comprehensive Cancer Center73
Completed
Not Applicable
Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)Breast NeoplasmsLymphomaNCT04119154Harvard School of Public Health (HSPH)270
Completed
Not Applicable
Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation TherapyCancer of the Gastrointestinal, Genitourinary or Gynecologic SystemsNCT02407977Duke University13
Recruiting
Not Applicable
Preventing infusate injuries throughout a child’s hospitalisatioExtravasation injuries (caused by peripheral intravenous catheters of infants)Injuries and Accidents - Other injuries and accidentsACTRN12623000561684niversity of Queensland532
Not yet recruiting
Not Applicable
Validation study for rapid profiling of immunohistochemical markers for breast cancerPACTR202111860919273Aikili Biosystems Inc.40